Literature DB >> 28562511

Kawasaki Disease Complicated With Macrophage Activation Syndrome: A Systematic Review.

Susana García-Pavón1, Marco A Yamazaki-Nakashimada, Milton Báez, Karla L Borjas-Aguilar, Chiharu Murata.   

Abstract

Macrophage activation syndrome (MAS), also known as secondary hemophagocytic lymphohistiocytosis, is a rare and potentially fatal complication of Kawasaki disease (KD). We report 2 cases, performed a literature search, and analyze the characteristics of MAS associated with KD. A total of 69 patients were evaluated, 34 reported the date of the diagnosis of MAS and KD, 6% had a diagnosis of MAS before KD, 21% had a simultaneous presentation, and 73% had the diagnosis of MAS after KD. Different treatment approaches were observed with corticosteroids administered in 87%, cyclosporine in 49%, etoposide (VP-16) in 39%, and monoclonal anti-TNF in 6% of cases. Coronary abnormalities were especially high in this group of patients (46%) and 9 patients died (13%). The persistence of fever with splenomegaly, hyperferritinemia, thrombocytopenia, and elevated aspartate aminotransferase (AST) should prompt the consideration of MAS complicating KD.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28562511     DOI: 10.1097/MPH.0000000000000872

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  25 in total

1.  Clinical and laboratory features, treatment, and outcomes of macrophage activation syndrome in 80 children: a multi-center study in China.

Authors:  Li-Xia Zou; Yun Zhu; Li Sun; Hui-Hui Ma; Si-Rui Yang; Hua-Song Zeng; Ji-Hong Xiao; Hai-Guo Yu; Li Guo; Yi-Ping Xu; Mei-Ping Lu
Journal:  World J Pediatr       Date:  2019-10-14       Impact factor: 2.764

Review 2.  Macrophage activation syndrome in juvenile dermatomyositis: a systematic review.

Authors:  Dimitri Poddighe; Kaisar Dauyey
Journal:  Rheumatol Int       Date:  2019-09-16       Impact factor: 2.631

Review 3.  Pediatric macrophage activation syndrome, recognizing the tip of the Iceberg.

Authors:  Courtney Crayne; Randy Q Cron
Journal:  Eur J Rheumatol       Date:  2019-12-03

4.  Pediatric expert consensus on the application of glucocorticoids in Kawasaki disease.

Authors: 
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-03-15

Review 5.  Perspective of Immunopathogenesis and Immunotherapies for Kawasaki Disease.

Authors:  Lung Chang; Horng-Woei Yang; Tang-Yu Lin; Kuender D Yang
Journal:  Front Pediatr       Date:  2021-07-19       Impact factor: 3.418

Review 6.  Kawasaki disease and immunodeficiencies in children: case reports and literature review.

Authors:  Francisco Rivas-Larrauri; Lorena Aguilar-Zanela; Paola Castro-Oteo; Luis Adrian Rosales-Hernandez; Francisco Otero-Mendoza; Gabriela López-Herrera; Javier Ordoñez-Ortega; Martín Garrido-García; Marco Antonio Yamazaki-Nakashimada
Journal:  Rheumatol Int       Date:  2019-07-16       Impact factor: 3.580

7.  COVID-19 multisystem inflammatory syndrome in three teenagers with confirmed SARS-CoV-2 infection.

Authors:  Khuen Foong Ng; Trishul Kothari; Srini Bandi; Paul William Bird; Kanika Goyal; Mohammad Zoha; Vinayak Rai; Julian Wei-Tze Tang
Journal:  J Med Virol       Date:  2020-07-06       Impact factor: 2.327

Review 8.  Macrophage activation syndrome: early diagnosis is key.

Authors:  Butsabong Lerkvaleekul; Soamarat Vilaiyuk
Journal:  Open Access Rheumatol       Date:  2018-08-31

9.  Pirfenidone suppresses polarization to M2 phenotype macrophages and the fibrogenic activity of rat lung fibroblasts.

Authors:  Michihito Toda; Shinjiro Mizuguchi; Yukiko Minamiyama; Hiroko Yamamoto-Oka; Takanori Aota; Shoji Kubo; Noritoshi Nishiyama; Toshihiko Shibata; Shigekazu Takemura
Journal:  J Clin Biochem Nutr       Date:  2018-04-11       Impact factor: 3.114

10.  An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study.

Authors:  Lucio Verdoni; Angelo Mazza; Annalisa Gervasoni; Laura Martelli; Maurizio Ruggeri; Matteo Ciuffreda; Ezio Bonanomi; Lorenzo D'Antiga
Journal:  Lancet       Date:  2020-05-13       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.